Previous Close | 63.92 |
Open | 64.07 |
Bid | 0.00 x 900 |
Ask | 0.00 x 1200 |
Day's Range | 60.74 - 64.32 |
52 Week Range | 20.63 - 82.00 |
Volume | |
Avg. Volume | 965,136 |
Market Cap | 2.677B |
Beta (5Y Monthly) | 1.95 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.67 |
Earnings Date | May 01, 2023 - May 05, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 107.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for AXSM
Three Fool.com contributors have ideas on up-and-coming growth stocks to buy right now. Here's why they chose Axsome Therapeutics (NASDAQ: AXSM), Sarepta Therapeutics (NASDAQ: SRPT), and Travere Therapeutics (NASDAQ: TVTX). Keith Speights (Axsome Therapeutics): Some small drugmakers have all of their eggs in one basket with only one pipeline candidate.
One is a well-established, large-cap drugmaker, while the other is still making a name for itself in the industry.
There are no guarantees that any stock will generate huge returns. But the odds look pretty good for these three growth stocks.